Evaluation of a new complement-dependent lymphocytotoxicity cross match method using an automated cell counter, the NucleoCounter® NC-3000™.
CDC cross match
NC-3000
transplantation
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
15
03
2023
received:
14
10
2022
accepted:
20
03
2023
medline:
17
5
2023
pubmed:
5
4
2023
entrez:
4
4
2023
Statut:
ppublish
Résumé
Complement-dependent lymphocytotoxicity cross match (CDC-XM) is the ultimate test of donor/recipient compatibility prior to organ transplantation. This test is based on cell viability, evaluated under fluorescence microscopy by an operator after proper staining. The determination of the positivity threshold may vary depending on the operator. We developed a new method in which the final step of determining cell viability is automated using the NC-3000™ (Chemometec®), an image cytometer able to precisely determine the percentage of dead/live cells in a suspension. After T and B donor cells isolation by negative selection, complement-dependent lysis was performed in macrovolumes in a PCR plate. Then, cell viability was measured by the NC-3000™. The sensitivity and routine CDC-XM results of this new method were compared to those of CDC-XM reference method using Terasaki plates. The sensitivity of CDC-XM expressed in the ASHI scoring system of this method was similar to the reference method results for a dilution range of the positive controls. Similarly, the results of the new method were comparable in a clinical situation to those obtained with the reference method after a study of 10 cross-matches, of which 5 cross-matches with DSA were positive and five cross-matches without DSA were negative. Moreover, ASHI scores were similar to those obtained using the reference method, and the mortality percentage was reproducible (CV < 15%). The assessment of cell viability by the NC-3000™ is easy to perform and highly reproducible but requires CDC-XM to be performed by the macrovolume method. The determination of a precise percentage of viability/mortality by the automation excludes operator variability and allows a better understanding of results close to the decision threshold.
Substances chimiques
Complement System Proteins
9007-36-7
HLA Antigens
0
Isoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
647-659Informations de copyright
© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.
Références
Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical application of the virtual crossmatch. Pediatr Transplant. 2007;11(6):650-654.
Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation. 2009;87(11):1681-1688.
Yanagida R, Czer LSC, Reinsmoen NL, et al. Impact of virtual cross match on waiting times for heart transplantation. Ann Thorac Surg déc. 2011;92(6):2104-2110. discussion 2111.
Israeli M, Pollack MS, Shaut CAE, et al. Concordance and discordance in anti-HLA antibody testing. Transpl Immunol Janv. 2015;32(1):1-8.
Vissal D. Anti-HLA antibodies: detection by cellular methods and crossmatch. Courr Transplant. 2018;XVIII(3-4):72-7.
Couzi L, Araujo C, Guidicelli G, et al. Interpretation of positive flow Cytometric Crossmatch in the era of the single-antigen bead assay. Transplantation. 2011;91(5):527-535.
Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant off J Am Soc Transplant Am Soc Transpl Surg Juill. 2014;14(7):1573-1580.
Terasaki PI, Mcclelland JD. Microdroplet assay of human serum cytotoxins. Nature déc. 1964;204(4962):998-1000.
Gebel HM, Lebeck LK. Crossmatch procedures used in organ transplantation. Clin Lab Med Sept. 1991;11(3):603-620.
Atale N, Gupta S, Yadav UCS, Rani V. Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques. J Microsc. 2014;255(1):7-19.
Al-Muzairai IA, Mansour M, Almajed L, Alkanderi N, Alshatti N, Samhan M. Heat inactivation can differentiate between IgG and IgM antibodies in the pretransplant cross match. Transplant Proc. 2008;40(7):2198-2199.
Hönger G, Krähenbühl N, Dimeloe S, Stern M, Schaub S, Hess C. Inter-individual differences in HLA expression can impact the CDC crossmatch. Tissue Antigens. 2015;85(4):260-266.
Kang H, Yoo J, Lee SY, Oh EJ. Causes of positive Pretransplant Crossmatches in the absence of donor-specific anti-human leukocyte antigen antibodies: a single-center experience. Ann. Lab Med. 2021;41(4):429-435.
Baranwal AK, Bhat DK, Goswami S, et al. Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with complement-dependent cytotoxicity & flow crossmatch results in live donor renal transplantation. Indian J Med Res févr. 2017;145(2):222-228.